MISSISSAUGA, Ontario, July 22 /PRNewswire-FirstCall/ —
CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), developer of
the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and
products for the immunoassay segment of the In-Vitro Diagnostics
market, announced that the Company’s ticker symbol has been changed
back to “CGNH” and the Company’s common stock began trading under
that new symbol yesterday.
About CardioGenics Holdings Inc.
Through its operating subsidiaries, the Company develops
ultra-sensitive analyzers and other products targeting the
immunoassay segment of the Point-Of-Care IVD testing market. It has
developed the QL Care™ Analyzer, a proprietary and
ultra-sensitive Point-Of-Care immuno-analyzer, which will run a
number of diagnostic tests under development, the first of which
will be a series of cardiovascular diagnostic tests. As part of its
core proprietary technology, the Company has also developed a
proprietary method for silver coating paramagnetic microspheres (a
fundamental platform component of immunoassay equipment), which
improve instrument sensitivity to light. The Company’s principal
offices are located in Mississauga,
Ontario, Canada. For more information please visit www.cardiogenics.com.
Safe Harbor Statement – Certain statements made herein that
are not historical are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995 and may contain
forward-looking statements, with words such as “anticipate,
“believe,” “expect,” “future,” “may,” “will,” “should,”
‘/>”/>
